IMUX insider transaction filings
IMMUNIC, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen IMUX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 18 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
+3 more insiders in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — IMMUNIC, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Nagel Robert Thorvald — Director | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | BVF PARTNERS L P/IL — Director BIOTECHNOLOGY VALUE FUND L P — Director BVF I GP LLC — Director BIOTECHNOLOGY VALUE FUND II LP — Director BVF II GP LLC — Director Biotechnology Value Trading Fund OS LP — Director BVF Partners OS Ltd. — Director BVF GP HOLDINGS LLC — Director BVF INC/IL — Director LAMPERT MARK N — Director | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | Ridloff Elena — Director | Grant/award (A): 50,740 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | Skerjanec Simona — Director | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | Rudick Richard Alan — Director | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | Neermann Joerg — Director | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | Congleton Jon — Director | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | PHILLIPS BARCLAY A — Director | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Congleton Jon — Director | Grant/award (A): 50,740 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Skerjanec Simona — Director | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Rudick Richard Alan — Director | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Neermann Joerg — Director | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Tardio Jason — President and COO | Grant/award (A): 253,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Whaley Glenn — Chief Financial Officer | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Vitt Daniel — Director | Grant/award (A): 445,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | PHILLIPS BARCLAY A — Director | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | BONNEY MICHAEL W — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | HOWSON TAMAR D — Director | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Lundgren Erik — Chief Executive Officer | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2026-04-29 | 4 | Panzara Michael A. — Chief Medical Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-07-18 | 4 | Whaley Glenn — Chief Financial Officer | Grant/award (A): 280,000 (derivative) @ $0 · Grant/award (A): 560,000 (derivative) @ $0 · Grant/award (A): 560,000 (derivative) @ $0 · Grant/award (A): 280,000 (derivative) @ $0 · Grant/award (A): 280,000 (derivative) @ $0 | EDGAR |
| 2025-07-18 | 4 | Nash Duane — Executive Chairman, Director | Grant/award (A): 315,000 (derivative) @ $0 · Grant/award (A): 630,000 (derivative) @ $0 · Grant/award (A): 630,000 (derivative) @ $0 · Grant/award (A): 315,000 (derivative) @ $0 · Grant/award (A): 315,000 (derivative) @ $0 | EDGAR |
| 2025-07-18 | 4 | Vitt Daniel — CEO and Director, Director | Grant/award (A): 860,000 (derivative) @ $0 · Grant/award (A): 1,720,000 (derivative) @ $0 · Grant/award (A): 1,720,000 (derivative) @ $0 · Grant/award (A): 860,000 (derivative) @ $0 · Grant/award (A): 860,000 (derivative) @ $0 | EDGAR |
| 2025-07-18 | 4 | Muehler Andreas — Chief Medical Officer | Grant/award (A): 330,000 (derivative) @ $0 · Grant/award (A): 660,000 (derivative) @ $0 · Grant/award (A): 660,000 (derivative) @ $0 · Grant/award (A): 330,000 (derivative) @ $0 · Grant/award (A): 330,000 (derivative) @ $0 | EDGAR |
| 2025-07-18 | 4 | Tardio Jason — President and COO | Grant/award (A): 330,000 (derivative) @ $0 · Grant/award (A): 660,000 (derivative) @ $0 · Grant/award (A): 660,000 (derivative) @ $0 · Grant/award (A): 330,000 (derivative) @ $0 · Grant/award (A): 330,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4/A | Tardio Jason — President and COO | Purchase (P): 12,512 @ $0.79 · Grant/award (A): 598,500 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4/A | Whaley Glenn — Chief Financial Officer | Grant/award (A): 503,500 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4/A | Vitt Daniel — CEO and Director, Director | Purchase (P): 15,000 @ $0.77 · Grant/award (A): 1,558,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4/A | Nash Duane — Executive Chairman, Director | Grant/award (A): 570,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4/A | Muehler Andreas — Chief Medical Officer | Grant/award (A): 598,500 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Nash Duane — Executive Chairman, Director | Purchase (P): 20,000 @ $0.83 | EDGAR |
| 2025-06-09 | 4 | Skerjanec Simona — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Rudick Richard Alan — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Toernsen Monika Maria — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Tardio Jason — President and COO | Purchase (P): 12,512 @ $0.79 · Grant/award (A): 595,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Neermann Joerg — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Whaley Glenn — Chief Financial Officer | Grant/award (A): 503,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Nash Duane — Executive Chairman, Director | Grant/award (A): 560,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Muehler Andreas — Chief Medical Officer | Grant/award (A): 595,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | PHILLIPS BARCLAY A — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | HOWSON TAMAR D — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Vitt Daniel — CEO and Director, Director | Purchase (P): 15,000 @ $0.77 · Grant/award (A): 1,535,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Neermann Joerg — Director | Purchase (P): 70,000 @ $0.77 · Purchase (P): 30,000 @ $0.76 | EDGAR |
| 2025-06-04 | 4 | Whaley Glenn — Chief Financial Officer | Grant/award (A): 25,000 @ $0.56 · Purchase (P): 45,000 @ $0.71 | EDGAR |
| 2025-06-04 | 4 | Rudick Richard Alan — Director | Purchase (P): 143,075 @ $0.70 | EDGAR |
| 2024-12-09 | 4/A | Nash Duane — Executive Chairman, Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2024-12-06 | 4 | Nash Duane — Executive Chairman, Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2024-12-06 | 4 | Muehler Andreas — Chief Medical Officer | Grant/award (A): 315,000 (derivative) @ $0 | EDGAR |
| 2024-12-06 | 4 | Tardio Jason — President and COO | Grant/award (A): 157,500 (derivative) @ $0 | EDGAR |
| 2024-12-06 | 4 | Whaley Glenn — Chief Financial Officer | Grant/award (A): 265,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — IMMUNIC, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-28 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IMUX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →